Japanese pharmaceutical giant Astellas is marking its 30th anniversary in the Chinese market, underscoring its commitment to expanding access to innovative medicines for patients across the Chinese mainland. Over the past three decades, Astellas has strengthened partnerships with local companies, fostering collaborations that drive pharmaceutical innovation and enhance healthcare outcomes.
In a recent interview with CGTN’s Wang Tianyu, Astellas’ Chief Commercial Officer, Claus Zieler, discussed the company’s journey in China and the evolving pharmaceutical landscape. Zieler highlighted how China’s advances in medicine approval processes have facilitated greater accessibility to cutting-edge treatments. \
Reference(s):
cgtn.com
